Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Apricus Biosciences Appoints As Chief Medical Officer

December 14, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 15, 2014 (GLOBE NEWSWIRE) — Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the appointment of Barbara Troupin, M.D., as the Company’s Chief Medical Officer. Dr. Troupin brings to Apricus…

Organovo Celebrates A Positive 2014 Reception Of Its exVive3DTM Human Liver Tissue Product

December 14, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 15, 2014 /PRNewswire/ — Organovo Holdings, Inc. (NYSE MKT: ONVO) (“Organovo”), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today celebrated continued positive reception by the industry and collaborators of its exVive3DTM Human…

Applied Proteomics, Inc. Appoints As Chief Financial Officer

December 14, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 16, 2014 /PRNewswire/ –Applied Proteomics Inc., the leading developer of protein-based molecular diagnostics, announced today the appointment of Steve R. Martin as chief financial officer…

Aptose Biosciences Announces Appointment Of To Board Of Directors

December 14, 2014 – 5:00 pm | Edit Post

Adds Commercial Expertise to BoardSAN DIEGO and TORONTO, Dec. 15, 2014 /PRNewswire/ – Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms…

Isis Pharmaceuticals, Inc. Initiates Phase 1/2 Study Of ISIS-DMPK Rx In Patients With Myotonic Dystrophy Type 1

December 14, 2014 – 5:00 pm | Edit Post

CARLSBAD, Calif., Dec. 16, 2014 /PRNewswire/ –Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a study for ISIS-DMPKRx in patients with Myotonic Dystrophy Type 1 (DM1). DM1 is a rare genetic neuromuscular disease caused by the production of toxic dystrophia myotonica…

Bruker S.A. Introduces BioScope Resolve High-Resolution BioAFM System

December 14, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–At the Sixth AFM BioMed Conference, Bruker (NASDAQ: BRKR) today announced the release of BioScope Resolve, a biological atomic force microscope (bioAFM) that features the highest resolution imaging and most complete cell mechanics capabilities available for use with an inverted optical microscope (IOM). The system incorporates Brukers proprietary PeakForce Tapping technology…

Sorrento Therapeutics, Inc. Announces Strategic Investment By And Collaboration With Nantworks Founder For The Advancement Of Cancer Immunotherapies

December 14, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 15, 2014 /PRNewswire/ –Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today that it has entered into a binding agreement with NantWorks founder, physician scientist, and biotechnology entrepreneur Dr…

Sorrento Therapeutics, Inc. Announces Strategic Investment By And Collaboration With Founder For The Advancement Of Cancer Immunotherapies

December 14, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 15, 2014 /PRNewswire/ –Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today that it has entered into a binding agreement with NantWorks founder, physician scientist, and biotechnology entrepreneur Dr…

Sophiris Bio Inc. Tanks As Phase 3 Data Indicates Drug May Not Be Effective; Stock Down -74.46% At 9:55AM ET On Monday

December 14, 2014 – 5:00 pm | Edit Post

Sophiris Bio Reports Administrative Interim Analysis For The “PLUS-1″ Phase 3 Trial Of PRX302 For Benign Prostatic HyperplasiaSAN DIEGO & VANCOUVER, British Columbia–(BUSINESS WIRE)–Sophiris Bio Inc. (NASDAQ: SPHS) (the Company or Sophiris), a biopharmaceutical company developing PRX30…

Sophiris Bio Inc. Reports Administrative Interim Analysis For The “PLUS-1″ Phase 3 Trial Of PRX302 For Benign Prostatic Hyperplasia

December 14, 2014 – 5:00 pm | Edit Post

SAN DIEGO & VANCOUVER, British Columbia–(BUSINESS WIRE)–Sophiris Bio Inc. (NASDAQ: SPHS) (the Company or Sophiris), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and the treatment of localized prostate cancer…